{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036226","form_type":"8-K/A","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.768291+00:00","generated_at":"2026-05-31T11:12:10.372309+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ginkgo Q2 revenue down 30% to $56M, launches RIF cutting 35% of workforce for >$85M annual savings","bullets":["Q2 total revenue $56M vs $81M YoY; Cell Engineering $36M (-20%), Biosecurity $20M (41% gross margin).","Loss from ops $(223)M incl. $72M restructuring costs; Adjusted EBITDA $(99)M vs $(80M) prior year.","Reduction in force impacting 35% of workforce, expected to yield >$85M annualized savings by mid-2025.","Restructuring costs estimated $18-22M in Cell Engineering; facilities consolidation underway.","FY 2024 outlook reaffirmed: total revenue $170-190M, Cell Engineering $120-140M, Biosecurity ≥$50M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036226","json":"https://secwatch.observer/filing/0001628280-24-036226.json","markdown":"https://secwatch.observer/filing/0001628280-24-036226.md","text":"https://secwatch.observer/filing/0001628280-24-036226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/0001628280-24-036226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/dna-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:12:10.372309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7d5cf3a90052863e4f186921ed2355c0858d875","claim":"Ginkgo Bioworks Holdings, Inc. announced a restructuring with charges of $18.0 million to $22.0 million affecting Cell Engineering segment (35% of the workforce).","evidence_excerpt":"The Company currently estimates the costs for the reduction in force to range from $18.0 million to $22.0 million primarily in the Cell Engineering segment and consist of one-time cash severance and related costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/0001628280-24-036226-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$18.0 million to $22.0 million"},{"label":"Affected area","value":"Cell Engineering segment"},{"label":"Headcount","value":"35% of the workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}